Rheumatoid arthritis–associated interstitial lung disease: Current approaches and HK data
17 Apr 2024;
Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA), contributing to increased morbidity and mortality. At a symposium during the 2023 International Conference of Chinese Rheumatologists (ICCR) held in Hong Kong, Professor Vanessa Smith of the Department of Internal Medicine, Ghent University, Ghent, Belgium, discussed the importance of early identification and management of patients with RA-ILD, and highlighted the value of the antifibrotic drug, nintedanib, in slowing lung function decline in progressive RAILD. Dr Shirley Chan of the Division of Rheumatology and Clinical Immunology, the University of Hong Kong, reported preliminary results from the RAISE study – a local study of RA-ILD screening and evaluation in high-risk RA patients.
Indications/Uses : Monotherapy for the treatment of adult patients w/ unresectable or metastatic HER2 +ve breast cancer who have received ≥1 prior anti-HER2-based regimens. Monotherapy for the treatment of adult patients w/ unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or w/in 6 mth of completing adjuvant chemotherapy. Monotherapy for the treatment of adult patients w/ advanced HER2 +ve gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Contents : Per actuation (delivered dose, ex-actuator) Budesonide 160 mcg, glycopyrronium 7.2 mcg, formoterol fumarate dihydrate 5 mcg
Indications/Uses : Maintenance treatment for moderate to severe COPD in adults who are not adequately treated by a combination of an inhaled corticosteroid & a long-acting β2-agonist or combination of a long-acting β2-agonist & a long-acting muscarinic antagonist.
Sign Out
